JP2022522787A5 - - Google Patents

Info

Publication number
JP2022522787A5
JP2022522787A5 JP2021551806A JP2021551806A JP2022522787A5 JP 2022522787 A5 JP2022522787 A5 JP 2022522787A5 JP 2021551806 A JP2021551806 A JP 2021551806A JP 2021551806 A JP2021551806 A JP 2021551806A JP 2022522787 A5 JP2022522787 A5 JP 2022522787A5
Authority
JP
Japan
Prior art keywords
amino acid
fusion protein
linker
terminus
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021551806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522787A (ja
JP7664168B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/077750 external-priority patent/WO2020177712A1/en
Publication of JP2022522787A publication Critical patent/JP2022522787A/ja
Publication of JP2022522787A5 publication Critical patent/JP2022522787A5/ja
Application granted granted Critical
Publication of JP7664168B2 publication Critical patent/JP7664168B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021551806A 2019-03-05 2020-03-04 ポリペプチド分子及びその適用 Active JP7664168B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910162060 2019-03-05
CN201910162060.6 2019-03-05
CN201910758104.1 2019-08-16
CN201910758104 2019-08-16
PCT/CN2020/077750 WO2020177712A1 (en) 2019-03-05 2020-03-04 A polypeptide molecule and application thereof

Publications (3)

Publication Number Publication Date
JP2022522787A JP2022522787A (ja) 2022-04-20
JP2022522787A5 true JP2022522787A5 (cg-RX-API-DMAC7.html) 2023-02-09
JP7664168B2 JP7664168B2 (ja) 2025-04-17

Family

ID=72338401

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021551806A Active JP7664168B2 (ja) 2019-03-05 2020-03-04 ポリペプチド分子及びその適用

Country Status (8)

Country Link
US (2) US12590132B2 (cg-RX-API-DMAC7.html)
EP (1) EP3935075A4 (cg-RX-API-DMAC7.html)
JP (1) JP7664168B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210137093A (cg-RX-API-DMAC7.html)
CN (2) CN118388627A (cg-RX-API-DMAC7.html)
AU (2) AU2020230668B2 (cg-RX-API-DMAC7.html)
CA (1) CA3123325A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020177712A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112661858A (zh) * 2020-12-03 2021-04-16 安徽安科生物工程(集团)股份有限公司 重组人生长激素Fc融合蛋白和用途及其工程细胞株
US20240165202A1 (en) * 2021-03-19 2024-05-23 Sunshine Lake Pharma Co., Ltd. Uses of fgf21 polypeptides and fusion polypeptides thereof
WO2023284822A1 (en) * 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
CN115991793A (zh) * 2023-01-16 2023-04-21 上海民为生物技术有限公司 具有多重活性的融合蛋白及其应用
KR20250140132A (ko) * 2023-01-18 2025-09-24 상하이 민웨이 바이오테크놀로지 씨오 엘티디 삼중 활성을 갖는 융합 단백질 및 그 용도
JP2026520995A (ja) * 2023-06-20 2026-06-25 サンシャイン・レイク・ファーマ・カンパニー・リミテッド GLP-1-Fc-FGF21二重標的融合タンパク質組成物、注射液、及びその使用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110893A (en) * 1995-06-05 2000-08-29 Human Genome Sciences, Inc. Fibroblast growth factor 11
ES2371072T3 (es) * 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
PL1751184T3 (pl) 2004-05-13 2010-02-26 Lilly Co Eli Białka fuzyjne FGF-21
BRPI0514790A (pt) 2004-09-02 2008-06-24 Lilly Co Eli muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
EP1789443A1 (en) 2004-09-02 2007-05-30 Eli Lilly And Company Muteins of fibroblast growth factor 21
JP2008522617A (ja) 2004-12-14 2008-07-03 イーライ リリー アンド カンパニー 線維芽細胞成長因子21の突然変異タンパク質
US20110034373A1 (en) 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
SG193860A1 (en) 2008-06-04 2013-10-30 Amgen Inc Fgf21 mutants and uses thereof
NZ592009A (en) 2008-10-10 2012-11-30 Amgen Inc Fgf21 mutants and uses thereof
DK3178835T3 (da) * 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
BRPI1011404B1 (pt) 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
CN101993496B (zh) 2009-08-20 2013-06-05 重庆富进生物医药有限公司 双重调节血糖血脂融合蛋白及其制法和用途
WO2013033452A2 (en) 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
US9458214B2 (en) * 2011-09-26 2016-10-04 Novartis Ag Dual function fibroblast growth factor 21 proteins
AR087973A1 (es) * 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
JP2015522539A (ja) 2012-05-15 2015-08-06 イーライ リリー アンド カンパニー 線維芽細胞増殖因子21タンパク質の治療目的の使用
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子21蛋白質
AU2013274639A1 (en) 2012-06-11 2014-11-06 Eli Lilly And Company Fibroblast growth factor 21 variants
AR092076A1 (es) 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
WO2015038938A1 (en) * 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2015061351A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
WO2016048999A2 (en) * 2014-09-23 2016-03-31 Salk Institute For Biological Studies Fgf21 truncations and mutants and uses thereof
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
CN106397569B (zh) * 2015-08-01 2020-09-01 深圳红石科创生物科技发展有限公司 一种治疗代谢疾病的突变细胞因子融合蛋白
CA3000697A1 (en) 2015-10-01 2017-04-06 Amgen Inc. Treatment of bile acid disorders
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
WO2017116207A1 (ko) * 2015-12-31 2017-07-06 한미약품 주식회사 Fgf21 아날로그, fgf21 결합체, 및 이의 용도
US20190142963A1 (en) 2016-04-15 2019-05-16 Richard D. DiMarchi Fgf21 c-terminal peptide optimization
CN107759697B (zh) * 2016-08-19 2023-03-24 安源医药科技(上海)有限公司 制备融合蛋白的方法
HUE071618T2 (hu) 2016-11-10 2025-09-28 Yuhan Corp Fúziós fehérjéket tartalmazó gyógyszerkészítmény hepatitisz, májfibrózis és májzsugor megelõzésére vagy kezelésére
CN108440668A (zh) 2017-02-16 2018-08-24 瑞阳(苏州)生物科技有限公司 Fgf21与igf-1的融合蛋白及其应用
WO2018166461A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CN108623691B (zh) * 2017-03-17 2020-05-15 北京比洋生物技术有限公司 IgG样长效免疫融合蛋白及其应用
CN116098989B (zh) * 2018-02-08 2026-03-20 广东东阳光药业股份有限公司 Fgf21变体、融合蛋白及其应用

Similar Documents

Publication Publication Date Title
JP6618854B2 (ja) 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
CN107074928B (zh) 新型猫促红细胞生成素受体激动剂
HRP20250309T1 (hr) Proteini s dvostrukom funkcijom i farmaceutski pripravak koji ih sadrži
JP2008500373A5 (cg-RX-API-DMAC7.html)
JPH07508025A (ja) インスリン様増殖因子(igf−1)類似体
US20180028676A1 (en) Methods and compositions for treatment of forbes-cori disease
JP2014524908A5 (cg-RX-API-DMAC7.html)
JP2015522576A (ja) 血小板由来成長因子に結合する設計アンキリンリピートタンパク質
JP2024532503A5 (cg-RX-API-DMAC7.html)
US20070244041A1 (en) Peptide Yy Analogues
JP2021512159A5 (cg-RX-API-DMAC7.html)
TW201536814A (zh) 用於治療心臟衰竭之合成環狀多肽
JP2023040169A5 (cg-RX-API-DMAC7.html)
CN102482324A (zh) 能够抑制自身免疫、炎症和癌症进程的新型趋化因子结合多肽
AU2022413461A1 (en) Designed repeat domains with dual binding specificity and their use
CN116615251A (zh) 包含glp1肽模拟物的抗体-药物缀合物及其用途
JP2026501203A (ja) アクチビン受容体iib型バリアント及びその使用
EP1590458A2 (en) Bradykinin b2 receptor antagonist peptide from amphibian skin
MX2012005912A (es) Conjugado de polipeptido.
WO2025096921A1 (en) Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
Mezo et al. Structure–activity relationships of a peptide inhibitor of the human FcRn: human IgG interaction
JP2022523047A5 (cg-RX-API-DMAC7.html)
JP2025516139A5 (cg-RX-API-DMAC7.html)
JP2024546916A5 (cg-RX-API-DMAC7.html)
JP2010535490A (ja) インスリン様成長因子融合タンパク質